查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953940

CT/NG檢測市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、檢測類型、技術、最終用戶、地區和競爭格局分類，2021-2031年）

CT/NG Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Testing Type, By Technology, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 CT/NG 影像市場預計將從 2025 年的 18.7 億美元成長到 2031 年的 31.1 億美元，複合年成長率為 8.84%。

該市場主要包括採用核酸擴增技術、專門用於定性檢測淋病奈瑟菌（Neisseria gonorrhoeae）和披衣菌感染（Chlamydia trachomatis）病原體的診斷設備系統和檢測方法。市場成長的主要促進因素是這些性行為感染傳染病在全球範圍內的發病率不斷上升以及政府主導的篩檢計畫的擴展。此外，在非傳統醫療機構中採用就地檢驗方法也加速了快速診斷工具的普及，有助於更快地治療並更好地管理疾病。

市場概覽
預測期 2027-2031
市場規模：2025年 18.7億美元
市場規模：2031年 31.1億美元
複合年成長率：2026-2031年 8.84%
成長最快的細分市場 檢測和試劑盒
最大的市場 北美洲

阻礙市場擴張的主要挑戰之一是這些疾病的社會污名化和無症狀感染的特點，這使得許多人不願意接受自願檢測。這一障礙限制了有效病例的發現，並降低​​了關鍵人群獲得診斷產品的機會。美國國家性傳染病主任聯盟強調了這種持續存在的疾病負擔，該聯盟報告稱，到2024年，美國將記錄超過220萬例披衣菌感染、淋病和梅毒病例。如此龐大的性行為感染人數表明，對健全的診斷檢測基礎設施的需求將持續存在。

市場促進因素

面向消費者的家用自採集試劑盒的普及顯著擴大了市場進入，避免了傳統診所檢測帶來的社會污名和後勤障礙。這一趨勢促進了診斷的廣泛應用，使個人能夠在私密環境中進行高精度檢測，這對於發現無症狀感染疾病至關重要。製造商正不斷獲得監管機構對其面向消費者的先進分子平台的核准，從而彌合了專業檢查室的精準度與消費者使用便利性之間的差距。據Visby Medical公司稱，在2025年3月的監管成就公告中，美國食品藥物管理局（FDA）批准了其女性性健康檢測套組作為全新醫療設備認證，使其成為首個核准用於檢測披衣菌感染和淋病的商用家用PCR診斷設備。

同時，向高靈敏度核酸增幅檢查(NAAT) 的技術轉型以及自動化高通量系統的整合正在簡化臨床工作流程，以滿足持續成長的檢測需求。實驗室優先選擇能夠快速出結果並整合檢測菜單的平台，以便在保持高特異性的同時高效處理大量檢體。這種營運效率的提升也體現在投資分子平台的主要產業參與者的財務表現。根據羅氏公司於 2025 年 1 月發布的《2024 年年度報告》，其診斷部門的銷售額達到 143 億瑞士法郎，核心業務成長 8%，主要得益於對免疫診斷和分子解決方案需求的成長。這種診斷能力對於公共衛生監測仍然至關重要。根據英國衛生安全局統計，上年度2025 年，英格蘭就記錄了 71,802總合淋病診斷病例，凸顯了建立健全的監測系統的必要性。

市場挑戰

與性行為感染傳染病相關的社會污名，加上披衣菌感染披衣菌和淋病奈瑟菌感染通常無症狀，對診斷市場的發展構成了重大障礙。患者在沒有出現任何身體症狀時往往不願就醫，而對社會評價的擔憂進一步抑制了自願篩檢。這種猶豫直接減少了患者主導諮詢醫療保健提供者的次數，並降低了診斷檢測套組和設備的整體使用率。因此，製造商面臨一個有限的市場，該市場主要以反應性檢測為主，而非預防性檢測，這大大限制了檢測套組的潛在消耗量。

這些持續存在的未被發現的感染病例凸顯了篩檢對市場的影響。病原體的無症狀傳播導致大量檢測機會的錯失，限制了診斷服務提供者的收入來源，並減緩了關鍵人口的市場滲透率。例如，美國縣市衛生專員協會預測，到2024年，先天性梅毒病例將增加2%，達到約4,000例，這反映了這些障礙所蘊含的潛在檢測價值。這項統計數據表明，未能及時發現無症狀感染是一個重大挑戰，並突顯了這些疾病的潛伏期如何成為全球檢測市場擴張的根本限制因素。

市場趨勢

市場正迅速轉向能夠同時檢測披衣菌感染披衣菌、淋病奈瑟菌以及常見共感染疾病（如黴漿菌支原體和陰道毛滴蟲）的多症候群檢測組合。這一轉變的驅動力源於臨床需求，即在一次診療中區分重疊的病原體，突破單靶點檢測的局限性，旨在改善抗生素管理。領先的症候群檢測組合供應商的強勁商業性表現也為這一市場趨勢提供了有力支撐。根據生物梅里埃公司於2025年3月發布的2024會計年度財務報告，該公司非呼吸道生物檢測組合的銷售額成長了17%，顯示在臨床工作流程中，全面感染疾病分析的應用正在加速。

隨著症候群檢測組合的興起，分子診斷遷移到分散式臨床機構（例如急診中心和門診診所）的趨勢也日益明顯。與居家檢測和集中式檢查室處理不同，此趨勢著重於在照護端實施快速PCR檢測，旨在透過實施即時治療通訊協定來最大限度地減少失訪患者。隨著醫療網路優先考慮更貼近病患的就醫途徑，這種分散式基礎設施的實體規模正在顯著擴大。根據丹納赫公司2025年1月發布的“2024年第四季度財報會議紀要”，Sepede分子診斷系統的全球裝機量實現了接近兩位數的成長，突破6萬台。這項里程碑式的成就主要得益於傳統醫院檢查室以外的其他醫療機構的快速部署。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球CT/NG檢查市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（檢測及試劑盒、儀器/分析設備）
    • 依檢測類型（實驗室檢測、即時檢測）
    • 透過科技（免疫診斷、恒溫核酸增幅技術、聚合酵素鏈鎖反應）
    • 依最終使用者（臨床檢查室、醫院/診所、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美CT/NG檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7.歐洲CT/NG檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8.亞太CT/NG檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲CT/NG檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲CT/NG檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球CT/NG偵測市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories Inc.
  • QIAGEN NV
  • PerkinElmer Inc.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Danaher Corporation
  • Becton, Dickinson, and Company

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23772

The Global CT and NG Testing Market is projected to expand from USD 1.87 Billion in 2025 to USD 3.11 Billion by 2031, reflecting a compound annual growth rate of 8.84%. This market encompasses diagnostic instrument systems and assays specifically engineered for the qualitative detection of Neisseria gonorrhoeae and Chlamydia trachomatis pathogens, predominantly employing nucleic acid amplification technologies. The market's trajectory is primarily propelled by the rising global incidence of these sexually transmitted infections alongside the broadening enforcement of government-led screening programs. Additionally, the incorporation of point-of-care testing methods within non-traditional healthcare environments is hastening the uptake of rapid diagnostic tools, thereby enabling prompter treatment and better disease management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.87 Billion
Market Size 2031USD 3.11 Billion
CAGR 2026-20318.84%
Fastest Growing SegmentAssays and Kits
Largest MarketNorth America

One significant challenge impeding market expansion is the social stigma and asymptomatic nature of these diseases, which frequently discourages individuals from seeking voluntary testing. This barrier limits effective case finding and reduces the utilization of diagnostic products in key demographics. The persistent disease burden is highlighted by the National Coalition of STD Directors, which reported that in 2024, more than 2.2 million cases of chlamydia, gonorrhea, and syphilis were recorded in the United States. This substantial volume of infections indicates a sustained demand for robust diagnostic testing infrastructure.

Market Driver

The proliferation of direct-to-consumer and at-home self-collection kits is significantly expanding market access by circumventing the social stigma and logistical barriers associated with traditional clinic-based testing. This driver is democratizing diagnostic availability, allowing individuals to perform high-accuracy testing in private settings, which is crucial for capturing asymptomatic infections that might otherwise go undetected. Manufacturers are increasingly securing regulatory approvals for sophisticated molecular platforms designed for lay users, bridging the gap between professional lab accuracy and consumer convenience. According to Visby Medical, in a March 2025 announcement regarding regulatory achievements, the U.S. Food and Drug Administration granted De Novo authorization for their Women's Sexual Health Test, establishing it as the first PCR diagnostic device approved for over-the-counter home use for the detection of chlamydia and gonorrhea.

Simultaneously, a technological shift toward high-sensitivity Nucleic Acid Amplification Tests and the integration of automated high-throughput systems are streamlining clinical workflows to meet sustained testing demand. Laboratories are prioritizing platforms that offer rapid turnaround times and consolidated menus to manage large sample volumes efficiently while maintaining high specificity. This operational efficiency is reflected in the financial performance of major industry players investing in molecular infrastructure. According to Roche, in the January 2025 'Annual Report 2024', the Diagnostics Division achieved sales of CHF 14.3 billion, with the base business growing by 8 percent largely due to increased demand for immunodiagnostic and molecular solutions. This diagnostic capacity remains critical for public health monitoring; according to the UK Health Security Agency, in 2025, a total of 71,802 diagnoses of gonorrhea were recorded for the preceding year in England alone, underscoring the continued necessity for robust surveillance systems.

Market Challenge

The social stigma associated with sexually transmitted infections, combined with the frequently asymptomatic presentation of Chlamydia trachomatis and Neisseria gonorrhoeae, creates a substantial barrier to the growth of the diagnostic market. When individuals do not experience physical symptoms, they often lack the motivation to seek medical attention, while fear of societal judgment further deters voluntary screening. This hesitation directly reduces the volume of patient-initiated visits to healthcare providers, thereby decreasing the overall utilization of diagnostic assays and instrumentation. Consequently, manufacturers face a restricted market where testing is primarily reactive rather than preventative, significantly suppressing the potential volume of assay consumption.

The persistence of these undetected infections highlights the market impact of this screening gap. Because these pathogens spread silently, a vast number of potential testing opportunities are missed, limiting revenue streams for diagnostic providers and stalling market penetration in key demographics. Illustrating the severity of missed detection due to these barriers, according to the National Association of County and City Health Officials, in 2024, congenital syphilis cases increased by 2% to nearly 4,000 cases. This statistic demonstrates the critical failure to capture asymptomatic infections in a timely manner, underscoring how the hidden nature of these diseases fundamentally curtails the expansion of the global testing market.

Market Trends

The market is increasingly shifting toward multiplex syndromic testing panels, which facilitate the simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and prevalent co-infections such as Mycoplasma genitalium and Trichomonas vaginalis. This transition is driven by the clinical necessity to distinguish between pathogens with overlapping symptoms in a single patient visit, moving beyond the limitations of single-target assays to improve antimicrobial stewardship. The operational momentum behind this approach is evidenced by the robust commercial performance of major syndromic panel providers. According to BioMerieux, in the March 2025 '2024 Financial Results', sales of the company's BIOFIRE non-respiratory panels increased by 17%, illustrating the accelerating uptake of comprehensive infectious disease profiling in clinical workflows.

Parallel to the rise of syndromic panels, there is a distinct transition of molecular diagnostics into decentralized clinical settings such as urgent care centers and outpatient clinics. Unlike at-home testing or central laboratory processing, this trend focuses on the professional administration of rapid PCR tests at the point of care to enable immediate treatment protocols, thereby minimizing the rate of patients lost to follow-up. The physical footprint of this decentralized infrastructure has widened significantly as healthcare networks prioritize near-patient accessibility. According to Danaher, in the January 2025 'Fourth Quarter 2024 Earnings Call Transcript', the global installed base of Cepheid molecular systems grew by high single digits to exceed 60,000 instruments, a milestone fueled largely by accelerated placements in alternate care sites beyond the traditional hospital laboratory.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories Inc.
  • QIAGEN N.V.
  • PerkinElmer Inc.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Danaher Corporation
  • Becton, Dickinson, and Company

Report Scope

In this report, the Global CT and NG Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CT and NG Testing Market, By Product

  • Assays And Kits
  • Instruments/Analyzers

CT and NG Testing Market, By Testing Type

  • Lab Tests
  • PoC Tests

CT and NG Testing Market, By Technology

  • Immunodiagnostics
  • Isothermal Nucleic Acid Amplification Technology
  • Polymerase Chain Reaction

CT and NG Testing Market, By End User

  • Clinical Laboratories
  • Hospitals & Clinics
  • Others

CT and NG Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CT and NG Testing Market.

Available Customizations:

Global CT and NG Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CT and NG Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Assays And Kits, Instruments/Analyzers)
    • 5.2.2. By Testing Type (Lab Tests, PoC Tests)
    • 5.2.3. By Technology (Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction)
    • 5.2.4. By End User (Clinical Laboratories, Hospitals & Clinics, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America CT and NG Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Testing Type
    • 6.2.3. By Technology
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States CT and NG Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Testing Type
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada CT and NG Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Testing Type
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico CT and NG Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Testing Type
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By End User

7. Europe CT and NG Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Testing Type
    • 7.2.3. By Technology
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany CT and NG Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Testing Type
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By End User
    • 7.3.2. France CT and NG Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Testing Type
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom CT and NG Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Testing Type
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy CT and NG Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Testing Type
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain CT and NG Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Testing Type
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By End User

8. Asia Pacific CT and NG Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Testing Type
    • 8.2.3. By Technology
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China CT and NG Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Testing Type
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By End User
    • 8.3.2. India CT and NG Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Testing Type
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan CT and NG Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Testing Type
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea CT and NG Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Testing Type
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia CT and NG Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Testing Type
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By End User

9. Middle East & Africa CT and NG Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Testing Type
    • 9.2.3. By Technology
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia CT and NG Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Testing Type
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE CT and NG Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Testing Type
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa CT and NG Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Testing Type
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By End User

10. South America CT and NG Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Testing Type
    • 10.2.3. By Technology
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil CT and NG Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Testing Type
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia CT and NG Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Testing Type
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina CT and NG Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Testing Type
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global CT and NG Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Hologic, Inc.
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. Abbott Laboratories Inc.
  • 15.5. QIAGEN N.V.
  • 15.6. PerkinElmer Inc.
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. Siemens Healthineers AG
  • 15.9. Danaher Corporation
  • 15.10. Becton, Dickinson, and Company

16. Strategic Recommendations

17. About Us & Disclaimer